RGS-GAIP-interacting protein controls breast cancer progression

Molecular Cancer Research

Volumn 8, Issue 12, 2010, Pages 1591-1600

  Wang, Ling ^a   Lau, Julie S ^a   Patra, Chitta Ranjan ^a,c   Cao, Ying ^a   Bhattacharya, Santanu ^a   Dutta, Shamit ^a   Nandy, Debashis ^a   Wang, Enfeng ^a   Rupasinghe, Chamila N ^b   Vohra, Pawan ^a   Spaller, Mark R ^b   Mukhopadhyay, Debabrata ^a,d  

^a MAYO CLINIC CANCER CENTER   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BINDING PROTEIN; CR 1023; GELATINASE B; MUTANT PROTEIN; PEPTIDE DERIVATIVE; PROTEIN CDC42; PROTEIN GIPC; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RGS PROTEIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; PDZ DOMAIN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 78650495520     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0209     Document Type: Article

References (27)

1. De Vries L, Lou XJ, Zhao G, Zheng B, Farquhar MG. GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP. Proc Natl Acad Sci USA 1998;95:12340-5.
2. Kedlaya RH, Bhat KM, Mitchell J, Darnell SJ, Setaluri V. TRP1 interacting PDZ-domain protein GIPC forms oligomers and is localized to intracellular vesicles in human melanocytes. Arch Biochem Biophys 2006;454:160-9.
3. Kirikoshi H, Katoh M. Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors. Int J Mol Med 2002;9:509-13.
4. Muders MH, Dutta SK, Wang L, Lau JS, Bhattacharya R, Smyrk TC, et al. Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Research 2006;66:10264-8.
5. Awan A, Lucic MR, Shaw DM, Sheppard F, Westwater C, Lyons SA, et al. 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun 2002;290:1030-6.
6. Lee JD, Hempel N, Lee NY, Blobe GC. The type III TGF-βeta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-βeta signaling. Carcinogenesis 2010;31:175-83.
7. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1- mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 2003;278: 48848-60.
8. Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, Wang L, et al. Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res 2009;15:4095-103.
9. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001;98:11598-603.
10. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 2002;21:1299-303. (Pubitemid 34185247)
11. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005;92:2097-101.
12. Cox G, O'Byrne KJ. Matrix metalloproteinases and cancer. Anticancer Res 2001;21:4207-19.
13. van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cells 2002;2:251-2.
14. Ridley AJ. Rho GTPases and cellmigration. J Cell Sci 2001;114:2713-22.
15. Arbiser JL. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: Evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Semin Cancer Biol 2004;14:81-91.
16. Fried L, Arbiser JL. The reactive oxygen-driven tumor: Relevance to melanoma. Pigment Cell Melanoma Res 2008;21:117-22.
17. Vogelstein B. Cancer. A deadly inheritance. Nature 1990;348:681-2.
18. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
19. Wang L, Mukhopadhyay D, Xu XL. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J 2006;20:1513-5.
20. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991;6:1791-7.
21. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, et al. Gain-offunction mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994; 145:702-14.
22. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
23. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
24. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000;275:11327-32.
25. Toschi E, Rota R, Antonini A, Melillo G, Capogrossi MC. Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase- 2 levels in p53-mutated human melanoma cells. J Invest Dermatol 2000;114:1188-94.
26. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8.
27. Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, et al. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase- 9 promoter activation: Implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res 2006;4:803-10.